ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) reached a new 52-week low during trading on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $29.00 to $25.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. ACADIA Pharmaceuticals traded as low as $17.56 and last traded […]
– As of December 31, 2023, Company had $201.4 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to the end of 2025 –
.
ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price objective trimmed by JPMorgan Chase & Co. from $29.00 to $25.00 in a research report report published on Monday, Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock. A number of other analysts also recently issued reports on the stock. JMP […]
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) hit a new 52-week low during trading on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $29.00 to $25.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. ACADIA Pharmaceuticals traded as low as $17.56 and […]